22 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... Disease in HIV-AIDS ... complex (MAC) disease ... #HIVAIDS #IDSA ... #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... Disease in HIV-AIDS ... complex (MAC) disease ... #HIVAIDS #IDSA ... #management #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
6.11.16,18,31,33,45,52,58) 0.5mL IM ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
itraconazolea 200 mg PO BID ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Treponema pallidum Infections (Syphilis) to Prevent Disease in HIV-AIDS
Early Stage (Primary, Secondary,
to guide management ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
General Management ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Treating Chagas Disease ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
20 mg/kg IV or IM ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
Simplex Virus (HSV) Infections ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
suspension 400 mg PO BID ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology